A modeling framework for the economic evaluation of baricitinib in moderate-to-severe rheumatoid arthritis

Objectives: The approval in more than 50 countries of baricitinib, an oral Janus Kinase inhibitor for the treatment of Rheumatoid Arthritis (RA), warrants a framework for corresponding economic eva...